ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; purified talc; iron oxide yellow; silicon dioxide; polyvinyl alcohol; macrogol 3350; sodium stearylfumarate; titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; polyvinyl alcohol; microcrystalline cellulose; silicon dioxide; sodium stearylfumarate; titanium dioxide; macrogol 3350; purified talc - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

इसराइल - अंग्रेज़ी - Ministry of Health

merck serono ltd - cetuximab - solution for infusion - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, ras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease

इसराइल - अंग्रेज़ी - Ministry of Health

roche pharmaceuticals (israel) ltd - bevacizumab - concentrate for solution for infusion - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.- avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. - avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. - avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.- avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.- avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).- avastin, in combination with carboplatin and gemcitabine, is indicated for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.- avastin ( bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents - avastin ( bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix.- bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. - bevacizumab, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (hcc) who have not received prior systemic therapy.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

merck europe b.v.  - cetuximab - head and neck neoplasms; colorectal neoplasms - antineoplastic agents - erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer:in combination with irinotecan-based chemotherapy;in first-line in combination with folfox;as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.for details, see section 5.1.erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:in combination with radiation therapy for locally advanced disease;in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - breast neoplasms - antineoplastic agents - ibrance is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.in pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - carcinoma, non-small-cell lung - antineoplastic agents - iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

roche registration gmbh - erlotinib - carcinoma, non-small-cell lung; pancreatic neoplasms - antineoplastic agents - non-small cell lung cancer (nsclc)tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.in patients with tumours without egfr activating mutations, tarceva is indicated when other treatment options are not considered suitable.when prescribing tarceva, factors associated with prolonged survival should be taken into account.no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with epidermal growth factor receptor (egfr)-ihc - negative tumours.pancreatic cancertarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.when prescribing tarceva, factors associated with prolonged survival should be taken into account.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

kci medical australia pty ltd -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - afatinib dimaleate, quantity: 73.9 mg - tablet, film coated - excipient ingredients: purified talc; polysorbate 80; indigo carmine aluminium lake; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; macrogol 400; hypromellose; microcrystalline cellulose; titanium dioxide; crospovidone - giotrif is indicated as monotherapy for the treatment of adult patients with:,? locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. tumours must have activating epidermal growth factor receptor (egfr) mutations.,? locally advanced or metastatic squamous non-small cell carcinoma of the lung progressing on or after platinum-based chemotherapy.